PMV Pharmaceuticals, Inc. (PMVP)

1,7500 +0,0400 (+2,34%) Börsenschluss: 04:00PM EDT

PMV Pharmaceuticals, Inc.

1 Research Way
Princeton, NJ 08540
United States
609 642 6670
https://www.pmvpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 63

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David H. Mack Ph.D.	Co-Founder, CEO, President & Director	881,08k	N/A	1962
Dr. Arnold J. Levine Ph.D.	Co-Founder, Director & Member of Scientific Advisory Board	140k	N/A	1940
Dr. Deepika Jalota Pharm.D.	Chief Development Officer	593,9k	N/A	1977
Dr. Thomas E. Shenk Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1947
Mr. Michael Carulli	Chief Financial Officer	N/A	N/A	1974
Mr. Robert Ticktin	General Counsel, Head of Operations & Company Secretary	N/A	N/A	1962
Mr. Tim Smith	Senior VP & Head of Corporate Development and Investor Relations	N/A	N/A	N/A
Ms. Crystal Zuckerman	Vice President of Human Resources	N/A	N/A	N/A
Dr. Binh Vu Ph.D.	Senior VP of Drug Discovery & CMC	N/A	N/A	N/A
Dr. Marc Fellous M.D.	Senior VP and Head of Clinical Development & Medical Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Corporate Governance

PMV Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 6, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.